Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (111-120 of 222) with videos related to

Pageof 23
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|September 4, 2015
Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York CityMatthew S Simon, Don Weiss, Anita Geevarughese, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
The American Journal of Managed Care|November 20, 2018
Cost of pharmacotherapy for opioid use disorders following inpatient detoxificationKathryn E McCollister, Jared A Leff, Xuan Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 24, 2010
Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor settingSerena P Koenig, Bruce R Schackman, Cynthia Riviere, et al.
The International Journal on Drug Policy|May 16, 2019
Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioidsJoshua A Barocas, Jake R Morgan, David A Fiellin, et al.
Antiviral Therapy|December 25, 2012
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV diseaseBruce R Schackman, David W Haas, Jessica E Becker, et al.
Annals of Internal Medicine|January 16, 2013
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United StatesRochelle P Walensky, Paul E Sax, Yoriko M Nakamura, et al.
Plos One|May 21, 2014
The hepatitis C cascade of care: identifying priorities to improve clinical outcomesBenjamin P Linas, Devra M Barter, Jared A Leff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2024
Economic Evaluation of Delivering an Evidence-Based Online HIV Prevention Program to MSM via Direct-To-Consumer Marketing Versus Community-Based Organization RecruitmentSarah Munroe, Bruce R Schackman, Krystal Madkins, et al.
Medical Care|February 11, 2020
Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized TrialJemima A Frimpong, Karen Shiu-Yee, Susan Tross, et al.
Pageof 23

Showing results (111-120 of 222) with videos related to

Sort By:
Pageof 23
Journal of Acquired Immune Deficiency Syndromes (1999)|September 4, 2015
Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York CityMatthew S Simon, Don Weiss, Anita Geevarughese, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
The American Journal of Managed Care|November 20, 2018
Cost of pharmacotherapy for opioid use disorders following inpatient detoxificationKathryn E McCollister, Jared A Leff, Xuan Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 24, 2010
Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor settingSerena P Koenig, Bruce R Schackman, Cynthia Riviere, et al.
The International Journal on Drug Policy|May 16, 2019
Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioidsJoshua A Barocas, Jake R Morgan, David A Fiellin, et al.
Antiviral Therapy|December 25, 2012
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV diseaseBruce R Schackman, David W Haas, Jessica E Becker, et al.
Annals of Internal Medicine|January 16, 2013
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United StatesRochelle P Walensky, Paul E Sax, Yoriko M Nakamura, et al.
Plos One|May 21, 2014
The hepatitis C cascade of care: identifying priorities to improve clinical outcomesBenjamin P Linas, Devra M Barter, Jared A Leff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 2, 2024
Economic Evaluation of Delivering an Evidence-Based Online HIV Prevention Program to MSM via Direct-To-Consumer Marketing Versus Community-Based Organization RecruitmentSarah Munroe, Bruce R Schackman, Krystal Madkins, et al.
Medical Care|February 11, 2020
Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized TrialJemima A Frimpong, Karen Shiu-Yee, Susan Tross, et al.
Pageof 23